Cargando…

Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma

BACKGROUND: Conventional chemotherapy and radiotherapy for the treatment of lymphoma have notable drawbacks, and passive immunotherapy using a monoclonal antibody is restricted to CD20-positive B cell lymphoma. Therefore, new treatment types are urgently required, especially for T cell lymphoma. One...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Jiang, He, Shiping, Du, Jie, Wang, Zhulin, Li, Wang, Chen, Xianxiong, Jiang, Wenqi, Zheng, Duo, Jin, Guangyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359787/ https://www.ncbi.nlm.nih.gov/pubmed/25887995 http://dx.doi.org/10.1186/s13045-015-0121-9

Ejemplares similares

Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib
por: Gao, Ningning, et al.
Publicado: (2016)

Synthetic MUC1 breast cancer vaccine containing a Toll-like receptor 7 agonist exerts antitumor effects
por: Liu, Yu, et al.
Publicado: (2020)

Vitamin D3 enhances the tumouricidal effects of 5-Fluorouracil through multipathway mechanisms in azoxymethane rat model of colon cancer
por: Refaat, Bassem, et al.
Publicado: (2015)

Anti-tumor Activity of Toll-Like Receptor 7 Agonists
por: Chi, Huju, et al.
Publicado: (2017)

Synergy of purine-scaffold TLR7 agonist with doxorubicin on systemic inhibition of lymphoma in mouse model
por: Gao, Dong, et al.
Publicado: (2017)

A Therapeutic Whole-Tumor-Cell Vaccine Covalently Conjugated with a TLR7 Agonist
por: Chi, Huju, et al.
Publicado: (2022)

Oxaliplatin-Based Platinum(IV) Prodrug Bearing Toll-like Receptor 7 Agonist for Enhanced Immunochemotherapy
por: Tang, Li, et al.
Publicado: (2019)

Breast Cancer Vaccine Containing a Novel Toll-like Receptor 7 Agonist and an Aluminum Adjuvant Exerts Antitumor Effects
por: Zhang, Shuquan, et al.
Publicado: (2022)

The Toll‐like receptor 7 agonist imiquimod increases ethanol self‐administration and induces expression of Toll‐like receptor related genes
por: Lovelock, Dennis F., et al.
Publicado: (2022)

Toll-like Receptor agonists and alpha-galactosylceramide synergistically enhance the production of interferon-gamma in murine splenocytes
por: Ando, Tatsuya, et al.
Publicado: (2013)

High-glucose administration induces glucose intolerance in mice: a critical role of toll-like receptor 4
por: Zhan, Xiandong, et al.
Publicado: (2019)

Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
por: Wang, Xiaodong, et al.
Publicado: (2018)

The Mechanisms of Cardiac Protection Using a Synthetic Agonist of Galanin Receptors during Chronic Administration of Doxorubicin
por: Studneva, I. M., et al.
Publicado: (2020)

Administration of an LXR agonist promotes atherosclerotic lesion remodelling in murine inflammatory arthritis
por: Dragoljevic, Dragana, et al.
Publicado: (2023)

Validation of DREADD agonists and administration route in a murine model of sleep enhancement
por: Ferrari, Loris L., et al.
Publicado: (2022)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice
por: Do, Kim Thi Hoang, et al.
Publicado: (2023)

A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model
por: Hu, Yunlong, et al.
Publicado: (2020)

Deposition of Doxorubicin in Rats following Administration of Three Newly Synthesized Doxorubicin Conjugates
por: Huan, Menglei, et al.
Publicado: (2013)

Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients
por: Winckelmann, Anni A., et al.
Publicado: (2013)

Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy
por: Dovedi, Simon J., et al.
Publicado: (2016)

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
por: Rolfo, Christian, et al.
Publicado: (2023)

Toll-like Receptor 4 Inflammatory Perspective on Doxorubicin-Induced Cardiotoxicity
por: Sumneang, Natticha, et al.
Publicado: (2023)

Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy
por: Chakraborty, Samik, et al.
Publicado: (2023)

Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells.
por: Ramu, A., et al.
Publicado: (1984)

T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
por: Moskowitz, Alison J., et al.
Publicado: (2022)

A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models
por: Adlard, Amy L, et al.
Publicado: (2014)

Activin A increases phagocytosis of Escherichia coli K1 by primary murine microglial cells activated by toll-like receptor agonists
por: Diesselberg, Catharina, et al.
Publicado: (2018)

A conjugate of octamer-binding transcription factor 4 and toll-like receptor 7 agonist prevents the growth and metastasis of testis embryonic carcinoma
por: Lin, Guimiao, et al.
Publicado: (2015)

The Toll-Like Receptor Agonist Imiquimod Is Active against Prions
por: Oumata, Nassima, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists in oncological indications
por: Aranda, Fernando, et al.
Publicado: (2014)

The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
por: Huang, Lingling, et al.
Publicado: (2022)

Protective Role of the Toll-Like Receptor 5 Agonist KMRC011 against Murine Colitis Induced by Citrobacter rodentium and Dextran Sulfate Sodium
por: Kim, Jun-Young, et al.
Publicado: (2023)

Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity
por: Lemos, Henrique, et al.
Publicado: (2020)

A Nonpeptide Oxytocin Receptor Agonist for a Durable Relief of Inflammatory Pain
por: Hilfiger, Louis, et al.
Publicado: (2020)

Toll-Like Receptor (TLR) 2 and TLR4 Differentially Regulate Doxorubicin Induced Cardiomyopathy in Mice
por: Ma, Yonggang, et al.
Publicado: (2012)

TREM1 is involved in the mechanism between asthma and lung cancer by regulating the Toll‑like receptor signaling pathway
por: Yan, Zhulin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3jqlc1g83ttre309vrtvcah3jo